

Anti-Cancer Drugs 2005

Author Index to Volume 16

- Aalbersberg W. *See* Richardson AD, 533
- Abe A *et al.* Growth inhibition and apoptosis induction of human melanoma cells by ω -hydroxy fatty acids, 543
- Abramjuk C *et al.* Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats, 855
- Adams BK *et al.* EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism, 263
- Adrian TE. *See* Ding X-Z, 467
- Ahmad KA *et al.* Targeting CK2 for cancer therapy, 1037
- Ahmed K. *See* Ahmad KA, 1037
- Alberts SR. *See* Molina JR, 997
- Åleskog A *et al.* *In vitro* drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia, 277; *also see* Hallböök H, 631
- Alexandre J. *See* Mir O, 1017
- Alexandre Jérôme. *See* Durand J-P, 587
- Alley M. *See* Tudor G, 381
- Amador R. *See* Díaz R, 323
- Amsellem-Ouazana D. *See* Mir O, 1017
- Anderson MG. *See* Gu W-Z, 1059
- Aparicio J. *See* Díaz R, 323
- Appleyard VCL. *See* Mayer M, 805
- Arce-Salinas C. *See* Candelaria M, 923
- Arend D. *See* Brandon EFA, 935
- Arizcun A. *See* Gómez-Bernal A, 77
- Armaganidis Apostolos. *See* Kopterides P, 743
- Armstrong J. *See* Adams BK, 263
- Arsenou ES *et al.* Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation *in vitro* and on angiogenesis *in vivo*, 151; *also see* Papageorgiou A, 1075
- Asakage M. *See* Kawai K, 401
- Au-Yeung SCF. *See* To KKW, 825
- Aubert C. *See* Bun S-S, 675
- Baas P. *See* Rademaker-Lakhai JM, 1029
- Bacci G. *See* Ferrari S, 733
- Bafaloukos D. *See* Markopoulos C, 879
- Baker B. *See* Singer JW, 243
- Bakoyannis C. *See* Razis E, 191
- Bang S-M. *See* Park S, 645
- Barbany G. *See* Hallböök H, 631
- Barthomeuf C. *See* Cabrespine A, 417
- Bartoletti R. *See* Neri B, 63
- Bartsch R. *See* Wenzel C, 441; *also et al.* Darbepoetin α as treatment for anemia in patients receiving chemotherapy: a single-center experience, 617
- Basile M. *See* Caponigro F, 211
- Bastert G. *See* Eichbaum MHR, 199
- Bauss F *et al.* Ibandronate in metastatic bone disease: a review of preclinical data, 107
- Bay J-O. *See* Cabrespine A, 417
- Beijnen JH. *See* de Jonge ME, 331; *also* Kappelhoff BS, 627; *also* den Brok MWJ, 727; *also* Brandon EFA, 935; *also* Rademaker-Lakhai JM, 1029
- Bell RH. *See* Ding X-Z, 467
- Belozarov VE *et al.* Hypoxia inducible factor-1: a novel target for cancer therapy, 901
- Beltrán A. *See* Díaz R, 323
- Benepal TS *et al.* ZD9331: discovery to clinical development, 1
- Benzo A. *See* Bigioni M, 1083
- Bernareggi A. *See* Singer JW, 243
- Berndtson AK. *See* Reed CA, 559
- Bernstein ML. *See* Lemaire M, 301
- Besman M. *See* Singer JW, 243
- Beuzeboc P. *See* Mir O, 1017
- Beyer U. *See* Hofheinz R-D, 691
- Bhandari P. *See* Mercer SJ, 495
- Bigda J. *See* Okrój M, 817
- Bigioni M *et al.* Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231, 1083
- Björnberg A. *See* Hallböök H, 631
- Blanco-Aparicio C *et al.* Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria, 977
- Blasiak J. *See* Olas B, 659
- Blohmer J-U. *See* Schmid P, 21
- Blomqvist C. *See* Villman K, 609
- Body J-J. *See* Bauss F, 107
- Bohm L. *See* Smit T, 501
- Boos J. *See* Gerth HUV, 101; *also* Oechtering D, 337
- Brandon EFA *et al.* In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction, 935
- Brantley E *et al.* The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF- κ B activity in drug-sensitive MCF-7 cells, 137
- Braumann C. *See* Jacobi CA, 917
- Braun A *et al.* The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan, 1099
- Briasoulis E. *See* Razis E, 191
- Brodowicz T. *See* Köstler WJ, 185
- Brown JL. *See* Harris SM, 945
- Bruce IA *et al.* Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer, 719
- Bun H. *See* Bun S-S, 675
- Bun S-S *et al.* Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs, 675
- Cabrespine A *et al.* *In vitro* assessment of cytotoxic agent combinations for hormone-

- refractory prostate cancer treatment, 417
- Caciagli B. *See* Coronello M, 621
- Cai J. *See* Adams BK, 263
- Cai R-Z. *See* Kanashiro CA, 159
- Calderero V. *See* Díaz R, 323
- Candelaria M *et al.* Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives, 923
- Caponigro F *et al.* New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17–18 June 2004, 211
- Carneiro-Leão AA. *See* Mayer M, 805
- Carnero A. *See* Blanco-Aparicio C, 977
- Carr BI. *See* Enokimura N, 837
- Casero RA. *See* Huang Y, 229
- Catalán R. *See* Morote J, 863
- Cecchini L. *See* Morote J, 863
- Celik I. *See* Gonen C, 59
- Cemazar M. *See* Snoj M, 345
- Cesari M. *See* Ferrari S, 733
- Cetinkaya YS. *See* Gonen C, 59
- Chaigneau L. *See* Royer B, 1009
- Challa EE. *See* den Brok MWJ, 727
- Chang C-H. *See* Kuo P-L, 789
- Chang J-K. *See* Kuo P-L, 409
- Chang J. *See* Wang H-M, 447
- Chang JC. *See* Zell JA, 83
- Charlton PA. *See* Harris SM, 945
- Chauffert B. *See* Royer B, 1009
- Chen I-H. *See* Wang H-M, 447
- Chen J-S *et al.* Phase I dose escalation study of oxaliplatin combined with oral tegafur–uracil and leucovorin in patients with advanced gastric cancer, 47
- Chen S. *See* Hu J, 119
- Chen Y-J. *See* Liao H-F, 175; *also et al.* Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells, 293
- Chen Y. *See* Zhang Y-X, 515
- Chen Z. *See* Hu J, 119
- Cheng A-L. *See* Yeh K-H, 739
- Cheong J. *See* Park C, 507
- Chernozemsky I. *See* von Minckwitz G, 871
- Cheung RY *et al.* *In vivo* efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations, 423
- Chilingirov P. *See* von Minckwitz G, 871
- Cho E. *See* Park S, 645
- Choi BT. *See* Park C, 507
- Choi E. *See* Park S, 645
- Choi YH. *See* Park C, 507
- Chollet P. *See* Cabrespine A, 417; *also* Thivat E, 1003
- Chow KU. *See* Trojan J, 87
- Chrissochou M. *See* Markopoulos C, 879
- Chung M. *See* Park S, 645
- Chvapil M *et al.* Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens, 201; *also* Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice, 757
- Ciccolini J. *See* Fischel J-L, 309; *also* Bun S-S, 675
- Ciciani G. *See* Coronello M, 621
- Ciolino HP. *See* Brantley E, 137
- Cipriani G. *See* Neri B, 63
- Cohen J. *See* Gu W-Z, 1059
- Coleman RE. *See* Woodward JKL, 11; *also* Woodward JKL, 845
- Combe M. *See* Royer B, 1009
- Comijn EM. *See* Temmink OH, 285
- Conroy M. *See* Knight LA, 969
- Coradini D. *See* Speranza A, 373
- Coronnello M *et al.* Cytotoxic activity of 3-nitropyrzolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents, 621
- Cortés-Funes H. *See* Quintela-Fandino M, 31; *also* Jimeno A, 53
- Costanzo A. *See* Coronello M, 621
- Covell DG. *See* Tudor G, 381
- Cree IA. *See* Mercer SJ, 495; *also* Knight LA, 969
- Crul M. *See* Rademaker-Lakhai JM, 1029
- Cruz J. *See* Gómez-Bernal A, 77
- Cure H. *See* Thivat E, 1003
- Curé Hervé. *See* Cabrespine A, 417
- Czerwenka K. *See* Hudelist G, 683
- D'Incalci M. *See* Riccardi A, 811
- D'Incan M. *See* Thivat E, 1003
- Dachs GU *et al.* From bench to bedside for gene-directed enzyme prodrug therapy of cancer, 349
- Daniewski WM. *See* Górka M, 776
- Davidson NE. *See* Huang Y, 229
- De Boeck G. *See* Dumez H, 885; 893
- de Bruijn EA. *See* Dumez H, 885, 893
- de Bruin M. *See* Temmink OH, 285
- de Jonge ME *et al.* Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes, 331
- De Mulder PHM. *See* van Spronsen DJ, 709; *also* Denissen NHAM, 897
- de Weijer KJM. *See* van Spronsen DJ, 709
- DeAngelis LM. *See* Gu B, 167
- Debiton E. *See* Cabrespine A, 417
- Debré B. *See* Mir O, 1017
- Della Melina A. *See* Neri B, 63
- Delroeux D. *See* Royer B, 1009
- Demopoulos NA. *See* Kouloumenta A, 67
- den Brok MWJ *et al.* Compatibility and stability of Imexon in infusion devices and its *in vitro* biocompatibility, 727
- Denissen NHAM *et al.* Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy, 897
- Dequiedt F. *See* Wittich S, 635
- Di Cello V. *See* Neri B, 63
- Di Nicolantonio F. *See* Mercer SJ, 495
- Díaz R *et al.* Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience, 323
- Dieckmann K. *See* Schönegger K, 1139
- Dieing A. *See* Schmid P, 21
- Dimopoulos M. *See* Razis E, 191
- Ding J. *See* Zhang Y-X, 515
- Ding X-Z *et al.* A novel anti-pancreatic cancer agent, LY293111, 467
- Ding Z-Y. *See* Wu Y, 551

- Dirsch O. *See* Braun A, 1099
- Dominici A. *See* Neri B, 63
- Dong Y. *See* Hu J, 119
- Doroshov JH. *See* Lara PN, 317
- Dorr R. *See* Chvapil M, 757
- Dueñas-Gonzalez A. *See* Candelaria M, 923
- Dumez H *et al.* *In vitro* partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender, 885; *also In vitro* partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking, 893
- Durand J-P *et al.* Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy, 587
- Durando X. *See* Thivat E, 1003
- Efstathiou H. *See* Razis E, 191
- Eggemann H. *See* Schmid P, 21
- Eggermont AMM. *See* Hoving S, 667
- Eichbaum MH R *et al.* Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab, 199
- Elling D. *See* Schmid P, 21
- Engels K. *See* Trojan J, 87
- Enokimura N *et al.* Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway, 837
- Erlichman C. *See* Molina JR, 997
- Esquena S. *See* Morote J, 863
- Faircloth GT. *See* Riccardi A, 811
- Fanciullino R. *See* Bun S-S, 675
- Fang J. *See* Hu J, 119
- Fardel O. *See* Massart C, 255
- Fergelot P. *See* Massart C, 255
- Ferguson D. *See* Gu W-Z, 1059
- Fernando A. *See* Mercer SJ, 495; *also* Knight LA, 969
- Ferrari S *et al.* Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate, 733
- Ferrero J-M. *See* Fischel J-L, 309
- Fiebig H-H. *See* Kelter G, 1091
- Fischel J-L *et al.* Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells, 309
- Flam T. *See* Mir O, 1017
- Fleischack G. *See* Oechtering D, 337
- Fleissner C. *See* Zavrski I, 475
- Flescher E. *See* Jasmonates—a new family of anti-cancer agents, 911
- Fletcher JA. *See* Labropoulos SV, 461
- Fominaya Jesús. *See* Blanco-Aparicio C, 977
- Fonseca E. *See* Gómez-Bernal A, 77
- Forkert R. *See* Stier S, 1115
- Formento J-L. *See* Fischel J-L, 309
- Formento P. *See* Fischel J-L, 309
- Fountzilas G. *See* Razis E, 191
- Fousteris MA. *See* Papageorgiou A, 1075
- Frankel P. *See* Lara PN, 317
- Fritze D. *See* von Minckwitz G, 871
- Fronhoffs S. *See* Stier S, 1115
- Frost D. *See* Gu W-Z, 1059
- Fukuoka M. *See* Tsuboi M, 1123
- Fukushima M. *See* Temmink OH, 285
- Fulignati C. *See* Neri B, 63
- Furth A. *See* Molina JR, 997
- Fussenegger M. *See* Gonzalez-Nicolini V, 223
- Gabriel FG. *See* Mercer SJ, 495
- Gajkowska B. *See* Górka M, 776
- Gandara DR. *See* Lara PN, 317
- García-Velasco A. *See* Quintela-Fandino M, 31
- Garde S. *See* Shukeir N, 1045
- Gelpi E. *See* Schönegger K, 1139
- Georg Opitz H. *See* den Brok MWJ, 727
- Gerhäuser C. *See* Wittich S, 635
- Gerth HUV *et al.* Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines, 101
- Giacometti S. *See* Bun S-S, 675
- Gibassier J. *See* Massart C, 255
- Gimenez-Bonafé P. *See* Llagostera E, 393
- Gnad-Vogt S *et al.* Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial, 435; *also see* Hofheinz R-D, 691
- Gnad-Vogt U. *See* Hofheinz R-D, 39
- Gnant MF. *See* Wenzel C, 441
- Godlewski MM. *See* Górka M, 776
- Gogas H. *See* Markopoulos C, 879
- Goldwasser F. *See* Durand J-P, 587; *also see* Mir O, 1017
- Gómez-Bernal A *et al.* Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer, 77
- Gonen C *et al.* Cytarabine-induced fever complicating the clinical course of leukemia, 59
- Gonzalez E. *See* Quintela-Fandino M, 31
- Gonzalez-Nicolini V *et al.* *In vitro* assays for anticancer drug discovery—a novel approach based on engineered mammalian cell lines, 223
- Górka M *et al.* Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel, 776
- Goso C. *See* Bigioni M, 1083
- Gravalos C. *See* Quintela-Fandino M, 31
- Gruhn B. *See* Oechtering D, 337
- Gu B *et al.* Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells, 167
- Gu R. *See* Lynch ED, 569
- Gu W-Z *et al.* A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies, 1059
- Guardiola E. *See* Royer B, 1009
- Guerrini G. *See* Coronello M, 621
- Guetens G. *See* Dumez H, 885; *also* Dumez H, 893
- Guillemin L. *See* Durand J-P, 587; *also* Mir O, 1017
- Gullbo J. *See* Lövborg H, 593
- Gumerlock PH. *See* Lara PN, 317

- Guo X-N. *See* Zhang Y-X, 515
 Gutierrez P. *See* Tudor G, 381
 Gutkind J. *See* Brantley E, 137
- Hahn M. *See* Schneeweiss A, 1023
 Hainfellner JA. *See* Schönegger K, 1139
 Hallböök H *et al.* *In vitro* activity of imatinib in cells from patients with adult acute lymphoblastic leukemia, 631
 Halmos G. *See* Kanashiro CA, 159
 Hanauske A-R. *See* Oberschmidt O, 1071
 Harlan JE. *See* Gu W-Z, 1059
 Harris SM *et al.* Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma, 945
 Hasinoff BB. *See* Wu X, 93
 Hassler M. *See* Schönegger K, 1139
 Haznedaroglu I. *See* Gonen C, 59
 Hegele A. *See* Schrader AJ, 581
 Hehlmann R. *See* Hofheinz R-D, 39; *also* Gnad-Vogt S, 435
 Heidenreich A. *See* Schrader AJ, 581
 Heilmann V. *See* Schmid P, 21
 Heim M *et al.* The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines, 129
 Heinemann V. *See* Stemmler HJ, 1135
 Heltweg B. *See* Wittich S, 635
 Hempel G. *See* Oechtering D, 337
 Herold M. *See* Adams BK, 263
 Heyd B. *See* Royer B, 1009
 Hiddemann W. *See* Stemmler HJ, 747
 Highley MS. *See* Dumez H, 885; *also* Dumez H, 893
 Hilger R. *See* Braun A, 1099
 Hirata E. *See* Nagai N, 525
 Hitt R. *See* Jimeno A, 53
 Hitzl W. *See* Reitsamer R, 867
 Ho L-T. *See* Chen Y-J, 293
 Ho Y-P. *See* To KKW, 825
 Hochhaus A. *See* Gnad-Vogt S, 435; *also* Hofheinz R-D, 39; 691
 Hoefs JC. *See* Zell JA, 83
 Hofheinz R-D *et al.* Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/ folinic acid in advanced colorectal cancer: a phase II study, 39; *also* Liposomal encapsulated anti-cancer drugs, 691; *also see* Gnad-Vogt S, 435
 Hofmann R. *See* Schrader AJ, 581
 Höglund M. *See* Åleskog A, 277
 Hoizey G. *See* Royer B, 1009
 Holbeck S. *See* Moreau P, 145
 Holen I. *See* Woodward JKL, 11; *also* Woodward JKL, 845
 Holzman T. *See* Gu W-Z, 1059
 Homer JJ. *See* Bruce IA, 719
 Hose CD. *See* Brantley E, 137
 Hosoda S. *See* Yurimoto S, 1109
 Hountala M. *See* Arsenou ES, 151
 Hoving S *et al.* Addition of low-dose tumor necrosis factor- α to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats, 667
 Hsu Y-L. *See* Kuo P-L, 409; *also* Kuo P-L, 789
 Hsueh C-T. *See* Wang H-M, 447
 Hu B. *See* Wu Y, 551
 Hu J *et al.* Arsenic in cancer therapy, 119
 Hua DH. *See* Wang Y, 953
 Huang J-S. *See* Chen J-S, 47
 Huang R. *See* Tudor G, 381
 Huang Y *et al.* Molecular mechanisms of polyamine analogs in cancer cells, 229
 Hudelist G. *See* Köstler WJ, 185; *also et al.* Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues, 683
 Huitema ADR. *See* de Jonge ME, 331; *also* Kappelhoff BS, 627
 Hussian D. *See* Wenzel C, 441; *also* Bartsch R, 617
- Ichinose Y. *See* Tsuboi M, 1123
 Ignatius Ou S-H. *See* Zell JA, 83
 Inoue H. *See* Enokimura N, 837
 Ireland CM. *See* Richardson AD, 533
 Irrissuto C. *See* Bigioni M, 1083
 Ishihara S. *See* Kaira K, 455
 Iwasaki Y. *See* Kaira K, 455
 Jacobi CA *et al.* Taurolidine—a new drug with anti-tumor and anti-angiogenic effects, 917
 Jaehde U. *See* Heim M, 129
 Jakesz R. *See* Wenzel C, 441
 Jakob C. *See* Zavrski I, 475
 Jakob CG. *See* Gu W-Z, 1059
 Jancar B. *See* Snoj M, 345
 Jarvis KP. *See* Gu W-Z, 1059
 Jiang H. *See* Tsuboi M, 1123
 Jimeno A *et al.* Phase II trial of vinorelbine tartrate in patients with treatment-naïve metastatic melanoma, 53
 Jimeno J. *See* Riccardi A, 811
 Jing N *et al.* Targeting Stat3 in cancer therapy, 601
 Jones DP. *See* Adams BK, 263
 Jordá MV. *See* Díaz R, 323
 Joseph I. *See* Gu W-Z, 1059
 Joshi R. *See* Llagostera E, 393
 Juchem R. *See* Abramjuk C, 855
 Judson I. *See* Benepal TS, 1
 Jung K. *See* Abramjuk C, 855
 Jung M. *See* Wittich S, 635
 Kahlert S. *See* Stemmler HJ, 1135
 Kaira K *et al.* Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer, 455
 Kaiser M. *See* Zavrski I, 475
 Kamano T. *See* Yurimoto S, 1109
 Kamysz W. *See* Okrój M, 817
 Kan B. *See* Wu Y, 551
 Kanashiro CA *et al.* Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma, 159
 Kanbe Y. *See* Yoneya T, 751
 Kang KI. *See* Park C, 507
 Kantelip J-P. *See* Royer B, 1009
 Kappelhoff BS *et al.* No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel, 627
 Kato H. *See* Tsuboi M, 1123
 Kaufmann M. *See* von Minckwitz G, 871
 Kawaguchi T. *See* Lara PN, 317
 Kawai K *et al.* Anti-angiogenic properties of plaunotol, 401
 Kawakita T. *See* Enokimura N, 837

- Kelter G *et al.* In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes, 1091
- Ki Lee W. *See* Park S, 645
- Kil J. *See* Lynch ED, 569
- Kim ND. *See* Park C, 507
- Kim S-Z. *See* Trojan J, 87
- Kitayama J. *See* Kawai K, 401
- Kleeberg U. *See* von Minckwitz G, 871
- Kliafa E. *See* Arsenou ES, 151
- Klijn JS. *See* Brandon EFA, 935
- Klingebiel T. *See* Oechtering D, 337
- Knight LA. *See* Mercer SJ, 495; *also et al.* Pilot studies of the effect of zoledronic acid (Zometa[®]) on tumor-derived cells *ex vivo* in the ATP-based tumor chemosensitivity assay, 969
- Ko Y. *See* Stier S, 1115
- Kobayashi H. *See* Nagai N, 525
- Kocijancic I. *See* Zwitter M, 1129
- Kolb HJ. *See* Stemmler HJ, 1135
- Koll C. *See* Stier S, 1115
- Komatsu M. *See* Nagai N, 525
- Kopterides P. *See* Razis E, 191; *also et al.* Cytarabine-induced lung injury: case report, 743
- Kornek GV. *See* Köstler WJ, 185
- Kosmidis P. *See* Razis E, 191
- Köstler WJ *et al.* Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience, 185
- Kouloumenta A *et al.* Genetic effects caused by potent antileukemic steroidal esters of chlorambucil's active metabolite, 67
- Koutsourea AI. *See* Papageorgiou A, 1075
- Kovac V. *See* Zwitter M, 1129
- Krainer M. *See* Köstler WJ, 185
- Krebbel H. *See* Zavrski I, 475
- Krebs B. *See* Gerth HUV, 101
- Kreil S. *See* Hofheinz R-D, 39; *also* Gnad-Vogt S, 435
- Krell H-W. *See* Abramjuk C, 855
- Kriener S. *See* Trojan J, 87
- Kristensen J. *See* Åleskog A, 277
- Krocker J. *See* Schmid P, 21
- Kroeger P. *See* Gu W-Z, 1059
- Kroutil A. *See* Sova P, 653
- Krych M. *See* Stemmler HJ, 747
- Kubista E. *See* Hudelist G, 683
- Kufe DW. *See* Mezhir JJ, 1053
- Kumar Pal S *et al.* Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy, 483
- Kuo C-D. *See* Chen Y-J, 293
- Kuo P-L *et al.* Induction of cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells by casuarinin from the bark of *Terminalia arjuna* Linn, 409; *also* The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction, 789
- Kuo Y-C. *See* Kuo P-L, 789
- Kuo Y-H. *See* Liao H-F, 175
- Kurbacher CM. *See* Knight LA, 969
- Kwon TK. *See* Park C, 507
- Labropoulos SV *et al.* Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate, 461
- Ladror US. *See* Gu W-Z, 1059
- Lamanna G. *See* Ferrari S, 733
- Lambropoulos S. *See* Razis E, 191
- Lanvers-Kaminsky C. *See* Gerth HUV, 101
- Lara PN *et al.* Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115776) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial, 317
- Larsson R. *See* Åleskog A, 277; *also* Lövborg H, 593; *also* Villman K, 609; *also* Hallböök H, 631
- Lathia CD. *See* Molina JR, 997
- Lau DHM. *See* Lara PN, 317
- Lauschner I. *See* Schneeweiss A, 1023
- Law LY. *See* Lara PN, 317
- Lázaro L. *See* Brandon EFA, 935
- Leal JF M. *See* Blanco-Aparicio C, 977
- Lee J. *See* Park S, 645
- Lee WH. *See* Park C, 507
- Lein M. *See* Abramjuk C, 855
- Lemaire M *et al.* Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia, 301
- Lenz H. *See* Lara PN, 317
- Li Q. *See* Wu Y, 551
- Liao C-T. *See* Wang H-M, 447
- Liao H-F *et al.* Compound 278E, structurally modified from tanshinone, induces monocytic differentiation and regulates proto-oncogene expression in human leukemic HL-60 cells, 175; *also see* Chen Y-J, 293
- Liau C-T. *See* Chen J-S, 47
- Lignos M. *See* Kopterides P, 743
- Lin C-C. *See* Kuo P-L, 409; 789
- Lin L-P. *See* Zhang Y-X, 515
- Lin N-H. *See* Gu W-Z, 1059
- Lin T-C. *See* Kuo P-L, 409
- Lin Y-C. *See* Chen J-S, 47
- Lindhagen E. *See* Åleskog A, 277; *also* Hallböök H, 631
- Lindhofer H. *See* Stemmler HJ, 1135
- Liotta DC. *See* Adams BK, 263
- Liu J-Y. *See* Wu Y, 551
- Liu T-Y. *See* Chen Y-J, 293
- Llagostera E *et al.* High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation, 393
- Loaiza-Pérez AI. *See* Brantley E, 137
- Locker GJ. *See* Köstler WJ, 185; *also* Wenzel C, 441; *also* Bartsch R, 617
- Loening SA. *See* Abramjuk C, 855
- Loibl S. *See* von Minckwitz G, 871
- Lou K. *See* Wang Y, 953
- Lövborg H *et al.* Screening for apoptosis—classical and emerging techniques, 593
- Lu YJ. *See* Adams BK, 263
- Luo Y. *See* Wu Y, 551
- Łusakowska E. *See* Górka M, 776
- Lutz C. *See* den Brok MWJ, 727
- Lynch ED *et al.* Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity, 569
- Madelmont J-C. *See* Thivat E, 1003
- Mader R. *See* Bartsch R, 617
- Maes RAA. *See* Dumez H, 885; *also* Dumez H, 893
- Maggi C. *See* Bigioni M, 1083

- Mairuhu ATA. *See* Kappelhoff BS, 627
- Majsterek I. *See* Olas B, 659
- Makatsoris T. *See* Razis E, 191
- Maleci D. *See* Neri B, 63
- Mao Y-Q. *See* Wu Y, 551
- Marabese M. *See* Riccardi A, 811
- Markopoulos C *et al.* Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy, 879
- Marosi C. *See* Köstler WJ, 185; *also* Schönegger K, 1139
- Marquez VE. *See* Lemaire M, 301
- Marschner N. *See* von Minckwitz G, 871
- Marsh K. *See* Gu W-Z, 1059
- Martín Germán. *See* Gómez-Bernal A, 77
- Martín T. *See* Gómez-Bernal A, 77
- Massari D *et al.* SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line, 989
- Massart C *et al.* Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells, 255
- Matula C. *See* Schönegger K, 1139
- Mayer M *et al.* Usnic acid: a non-genotoxic compound with anti-cancer properties, 805
- Mazzarella G. *See* Riccardi A, 811
- Mazzei T. *See* Coronello M, 621
- McGown AT. *See* Bruce IA, 719
- McLeod HL. *See* Morgensztern D, 797
- Meco D. *See* Riccardi A, 811
- Meijerman I. *See* Brandon EFA, 935
- Menenakos C. *See* Jacobi CA, 917
- Mentzelopoulos S. *See* Kopterides P, 743
- Menzel H. *See* Stemmler HJ, 1135
- Mercer SJ *et al.* Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors, 495
- Merkle K. *See* von Minckwitz G, 871
- Mezhir JJ *et al.* Chemoinducible gene therapy, 1053
- Michailidou A. *See* Markopoulos C, 879
- Michniewicz K. *See* Schmid P, 21
- Milano G. *See* Fischel J-L, 309
- Minamikawa K. *See* Nagai N, 525
- Minato K. *See* Kaira K, 455
- Mini E. *See* Coronello M, 621
- Mir O *et al.* Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities, 1017
- Misitzi J. *See* Markopoulos C, 879
- Mistr A. *See* Sova P, 653
- Mistry P. *See* Harris SM, 945
- Mitrou PS. *See* Trojan J, 87
- Miyakawa A. *See* Yurimoto S, 1109
- Molina JR *et al.* A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin, 997
- Momparler LF. *See* Lemaire M, 301
- Momparler RL. *See* Lemaire M, 301
- Moneo V. *See* Blanco-Aparicio C, 977
- Montaner B. *See* Llagostera E, 393
- Moreau P *et al.* Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines, 145
- Morgensztern D *et al.* PI3K/Akt/mTOR pathway as a target for cancer therapy, 797
- Mori M. *See* Kaira K, 455
- Morikawa K. *See* Yoneya T, 751
- Morote J *et al.* Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer, 863
- Motyl T. *See* Górka M, 776
- Mourelatos D. *See* Papageorgiou A, 1075
- Mouret-Reynier M-A. *See* Thivat E, 1003
- Muchmore SW. *See* Gu W-Z, 1059
- Mukai K. *See* Nagai N, 525
- Mulders PFA. *See* van Spronsen DJ, 709
- Mürdter T. *See* Oechtering D, 337
- Murray KE. *See* Mayer M, 805
- Mysliwski A. *See* Okrój M, 817
- Nagai K. *See* Tsuboi M, 1123
- Nagai N *et al.* Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test, 525
- Nagawa H. *See* Kawai K, 401
- Nakano T. *See* Enokimura N, 837
- Nelson CM. *See* Tudor G, 381
- Nephew KP. *See* Reed CA, 559
- Neri B *et al.* Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial, 63
- Neuhaus T. *See* Stier S, 1115
- Neuse EW. *See* Smit T, 501
- Neville-Webbe HL. *See* Woodward JKL, 845
- Ng S. *See* Gu W-Z, 1059
- Nicita G. *See* Neri B, 63
- Nienstedt D. *See* Singer JW, 243
- Nikolaropoulos SS. *See* Kouloumenta A, 67; *also* Arsenou ES, 151; *also* Papageorgiou A, 1075
- Niu T. *See* Wu Y, 551
- Normanno N. *See* Caponigro F, 211
- Nuijen B. *See* den Brok MWJ, 727
- Nygren P. *See* Åleskog A, 277; *also* Villman K, 609
- Oberschmidt O *et al.* Activity of [1,2-di(cyclopentadienyl)-1,2-di(*p*-*N,N*-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units, 1071
- O'Brien M. *See* Popat S, 361
- Oechtering D *et al.* Toxicity and pharmacokinetics of iv busulfan in children before stem cell transplantation, 337
- Ohlmann CH. *See* Schrader AJ, 581
- Okaji Y. *See* Kawai K, 401
- Okano H. *See* Enokimura N, 837
- Okrój M *et al.* A novel mechanism of action of the fumagillin analog, TNP-470, in the B16F10 murine melanoma cell line, 817
- Okuzawa A. *See* Yurimoto S, 1109
- Olas B *et al.* Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes, 659

- Olaverri A. *See* Gómez-Bernal A, 77
- Olbert P. *See* Schrader AJ, 581
- Oliveira AM. *See* Labropoulos SV, 461
- O'Neill MA. *See* Mayer M, 805
- Orsola A. *See* Morote J, 863
- Ostermann H. *See* Stemmler HJ, 747
- Panchal C. *See* Shukeir N, 1045
- Papadiamantis J. *See* Markopoulos C, 879
- Papadimitriou EP. *See* Arsenou ES, 151
- Papadopoulos S. *See* Razis E, 191; *also* Labropoulos SV, 461
- Papageorgiou A *et al.* Structure–anti-leukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil's active metabolite, 1075
- Pappa V. *See* Kopterides P, 743
- Paranjpe PV *et al.* Tumor-targeted and activated bioconjugates for improved camptothecin delivery, 763
- Park C *et al.* Induction of apoptosis and inhibition of cyclooxygenase-2 expression by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in human leukemia cells, 507
- Park S *et al.* Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes, 645
- Patel V. *See* Brantley E, 137
- Pectasides D. *See* Razis E, 191
- Pegram M. *See* Kumar Pal S, 483
- Peintinger F. *See* Reitsamer R, 867
- Pellizzaro C. *See* Speranza A, 373
- Pequeño B. *See* Blanco-Aparicio C, 977
- Perchellet EM. *See* Wang Y, 953
- Perchellet J-PH. *See* Wang Y, 953
- Pérez-Tomás R. *See* Llagostera E, 393
- Peters GJ. *See* Temmink OH, 285
- Peters R. *See* Abramjuk C, 855
- Pierce C. *See* Lynch ED, 569
- Pieretti F. *See* Ferrari S, 733
- Pilz L. *See* Hofheinz R-D, 39; *also* Gnad-Vogt S, 435
- Pivot X. *See* Royer B, 1009
- Planas J. *See* Morote J, 863
- Pledgie A. *See* Huang Y, 229
- Pluim D. *See* Rademaker-Lakhai JM, 1029
- Pluschnig U. *See* Wenzel C, 441; *also* Bartsch R, 617
- Poirier C. *See* Massart C, 255
- Polak M. *See* Knight LA, 969
- Polycarpe E. *See* Royer B, 1009
- Ponchietti R. *See* Neri B, 63
- Popat S *et al.* Chemotherapy strategies in the treatment of small cell lung cancer, 361
- Posner MC. *See* Mezhir JJ, 1053
- Possinger K. *See* Schmid P, 21; *also* Zavrski I, 475
- Pouckova P. *See* Sova P, 653
- Prayer D. *See* Schönegger K, 1139
- Prokop E. *See* Reitsamer R, 867
- Prudhomme M. *See* Moreau P, 145
- Quintela-Fandino M *et al.* Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer, 31; *also see* Jimeno A, 53
- Rabbani SA. *See* Shukeir N, 1045
- Rabitsch W. *See* Köstler WJ, 185
- Rademaker-Lakhai JM *et al.* Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer, 1029
- Radošević-Stašić B. *See* Massari D, 989
- Rau K-M. *See* Chen J-S, 47
- Raugei A. *See* Neri B, 63
- Rauth AM. *See* Cheung RY, 423
- Raventós CX. *See* Morote J, 863
- Razis E *et al.* Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program, 191
- Razis ED. *See* Labropoulos SV, 461
- Reed CA *et al.* Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor- α expression in the rat uterus, 559
- Rehmann F-JK. *See* Oberschmidt O, 1071
- Reid JM. *See* Molina JR, 997
- Reitsamer R *et al.* Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer, 867
- Renée N. *See* Fischel J-L, 309
- Rensburg CEJ. *See* Smit T, 501
- Reventós J. *See* Morote J, 863
- Reynés G. *See* Díaz R, 323
- Riccardi A *et al.* Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft, 811
- Riccardi R. *See* Riccardi A, 811
- Richardson AD *et al.* The patellazoles inhibit protein synthesis at nanomolar concentrations in human colon tumor cells, 533
- Rigatos S. *See* Razis E, 191
- Rodenhuis S. *See* de Jonge ME, 331
- Rodríguez CA. *See* Gómez-Bernal A, 77
- Rodríguez LE. *See* Gu W-Z, 1059
- Romero L. *See* Blanco-Aparicio C, 977
- Rompel A. *See* Gerth HUV, 101
- Robert S. *See* Mir O, 1017
- Rosa Vd. *See* Caponigro F, 211
- Rosche M. *See* Zavrski I, 475
- Rosenberg SH. *See* Gu W-Z, 1059
- Royer B *et al.* Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding, 1009
- Rudlowski C. *See* Schneeweiss A, 1023
- Rudolf Z. *See* Snoj M, 345
- Rukavina D. *See* Massari D, 989
- Saito H. *See* Yoneya T, 751
- Saito R. *See* Kaira K, 455
- Saitou Y. *See* Enokimura N, 837
- Sakamoto K. *See* Yurimoto S, 1109
- Sakamoto S. *See* Yurimoto S, 1109
- Salat C. *See* Stemmler HJ, 1135
- Salvador C. *See* Morote J, 863
- Samain E. *See* Royer B, 1009
- Sánchez P. *See* Gómez-Bernal A, 77
- Santos-Magalhães NS. *See* Mayer M, 805

- Sato K. *See* Kaira K, 455
- Saussele S. *See* Hofheinz R-D, 39;
also Gnad-Vogt S, 435
- Sausville EA. *See* Brantley E, 137;
also Moreau P, 145; also Tudor G, 381
- Schally AV. *See* Kanashiro CA, 159
- Scharifi M. *See* Heim M, 129
- Schellens JHM. *See* Kappelhoff BS, 627; also Brandon EFA, 935; also Rademaker-Lakhai JM, 1029
- Scherf H. *See* Wittich S, 635
- Schiltmeyer B. *See* Oechtering D, 337
- Schmid P *et al.* Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial, 21; also *see* Zavrski I, 475
- Schmidt H. *See* Mezhir JJ, 1053
- Schneeweiss A. *See* Eichbaum MHR, 199; also *et al.* Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial, 1023
- Schnorr J. *See* Abramjuk C, 855
- Schoenberg SO. *See* Stemmler HJ, 747
- Schönegger K *et al.* Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression, 1139
- Schrader AJ *et al.* Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma, 581
- Schuetz F. *See* Schneeweiss A, 1023
- Schulz C-O. *See* Schmid P, 21
- Schwab M. *See* Oechtering D, 337
- Scott JA. *See* Harris SM, 945
- Seeber S. *See* Heim M, 129; also Braun A, 1099
- Segedin B. *See* Zwitter M, 1129
- Segura Á. *See* Díaz R, 323
- Selleri S. *See* Coronello M, 621
- Senzer NN. *See* Mezhir JJ, 1053
- Serrano-Olvera A. *See* Candelaria M, 923
- Sersa G. *See* Snoj M, 345
- Seveldt U. *See* Wenzel C, 441; also Bartsch R, 617
- Seynhaeve ALB. *See* Hoving S, 667
- Sezer O. *See* Schmid P, 21; also Zavrski I, 475
- Shaffer S. *See* Singer JW, 243
- Sham HL. *See* Gu W-Z, 1059
- Sharma S. *See* Mercer SJ, 495
- Shen Y-C. *See* Yeh K-H, 739
- Shieh C-J. *See* Chen Y-J, 293
- Shin D. *See* Park S, 645
- Shiraki K. *See* Enokimura N, 837
- Shoji M. *See* Adams BK, 263
- Shukeir N *et al.* Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer, 1045
- Shyu S-Y. *See* Liao H-F, 175
- Singer CF. *See* Köstler WJ, 185; also Hudelist G, 683
- Singer JW *et al.* Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane, 243
- Sinko PJ. *See* Paranjpe PV, 763
- Sinn H-P. *See* Schneeweiss A, 1023
- Sirakova L. *See* von Minckwitz G, 871
- Skarlos D. *See* Razis E, 191
- Slaton J. *See* Ahmad KA, 1037
- Slevin NJ. *See* Bruce IA, 719
- Sloan JA. *See* Molina JR, 997
- Slominska EM. *See* Okrój M, 817
- Smilde TJ. *See* Denissen NHAM, 897
- Smit T *et al.* Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice, 501
- Smrdel U. *See* Zwitter M, 1129
- Snoj M *et al.* Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy, 345
- Snyder JP. *See* Adams BK, 263
- Snyman JR. *See* Smit T, 501
- Sohn C. *See* Schneeweiss A, 1023
- Somers SS. *See* Mercer SJ, 495
- Soto-Cerrato V. *See* Llagostera E, 393
- Souchon R. *See* von Minckwitz G, 871
- Souteyrand P. *See* Thivat E, 1003
- Sova P *et al.* Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12, 653
- Sparidans RW. *See* Brandon EFA, 935; also Rademaker-Lakhai JM, 1029
- Speranza A *et al.* Hyaluronic acid butyric esters in cancer therapy, 373
- Staack A. *See* Abramjuk C, 855
- Stark K. *See* Braun A, 1099
- Steger GG. *See* Köstler WJ, 185; also Wenzel C, 441; also Bartsch R, 617
- Stein S. *See* Paranjpe PV, 763
- Stemmler HJ *et al.* Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report, 747; also Lasting remission following multimodal treatment in a patient with metastatic breast cancer, 1135
- Stephan C. *See* Abramjuk C, 855
- Stephanou G. *See* Kouloumenta A, 67
- Stier S *et al.* Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study, 1115
- Stinson SF. *See* Brantley E, 137
- Stoll VS. *See* Gu W-Z, 1059
- Strohfeldt K. *See* Oberschmidt O, 1071; also Kelter G, 1091
- Stromatt S. *See* Singer JW, 243
- Strumberg D. *See* Heim M, 129
- Stuart N. *See* von Minckwitz G, 871
- Su J-M. *See* Wu Y, 551
- Sugimoto K. *See* Enokimura N, 837
- Sugiyama K. *See* Abe A, 543
- Sullivan GM. *See* Gu W-Z, 1059
- Sun A. *See* Adams BK, 263
- Sundström C. *See* Hallböök H, 631
- Sweeney N. *See* Oberschmidt O, 1071
- Sweeney NJ. *See* Kelter G, 1091
- Tacke M. *See* Oberschmidt O, 1071; also Kelter G, 1091
- Tada H. *See* Tsuboi M, 1123
- Taja-Chayeb L. *See* Candelaria M, 923
- Takahashi K. *See* Kawai K, 401
- Takei Y. *See* Kaira K, 455
- Takise A. *See* Kaira K, 455

- Talamonti MS. *See* Ding X-Z, 467
 Taniguchi K. *See* Yoneya T, 751
 Taymoorian K. *See* Abramjuk C, 855
 Temmink OH *et al.* Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells, 285
 ten Hagen TLM. *See* Hoving S, 667
 Thivat E *et al.* Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m²: a phase II trial, 1003
 Thompson AM. *See* Mayer M, 805
 Thomssen C. *See* von Minckwitz G, 871
 Tian L. *See* Wu Y, 551
 To KKW *et al.* *In vitro* and *in vivo* suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine–platinum anti-cancer agents, 825
 Toh SK. *See* Mercer SJ, 495
 Tolentinis L. *See* Ferrari S, 733
 Tozer GM. *See* Dachs GU, 349
 Trapani V. *See* Brantley E, 137
 Trilla E. *See* Morote J, 863
 Trobonjač Z. *See* Massari D, 989
 Trojan J *et al.* *In vitro* chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer, 87
 Tsai M-H. *See* Wang H-M, 447
 Tsai T-H. *See* Chen Y-J, 293
 Tsekov C. *See* von Minckwitz G, 871
 Tsuboi M *et al.* Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer, 1123
 Tsuchiya R. *See* Tsuboi M, 1123
 Tsuchiya S. *See* Kaira K, 455
 Tsunenari T. *See* Yoneya T, 751
 Tsuno NH. *See* Kawai K, 401
 Tudor G *et al.* Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction, 381
 Tuohimaa A. *See* Stier S, 1115
 Tupper J. *See* Dachs GU, 349
 Turrini M. *See* Neri B, 63
 Twardowski P. *See* Lara PN, 317
 Tweardy DJ. *See* Jing N, 601
 Tzamakou E. *See* Razis E, 191
 Tzoracoleftherakis E. *See* Markopoulos C, 879
 Ubezio P. *See* Riccardi A, 811
 Unger G. *See* Ahmad KA, 1037
 van Dam SM. *See* de Jonge ME, 331
 Van Meir EG. *See* Belozarov VE, 901
 van Oosterom AT. *See* Dumez H, 885
 van Oosterom AT. *See* Dumez H, 893
 van Spronsen DJ *et al.* Novel treatment strategies in clear-cell metastatic renal cell carcinoma, 709
 van Spronsen DJ. *See* Denissen NHAM, 897
 van Tiel ST. *See* Hoving S, 667
 van Zandwijk N. *See* Rademaker-Lakhai JM, 1029
 von Fournier D. *See* Schneeweiss A, 1023
 von Knobloch R. *See* Schrader AJ, 581
 von Minckwitz G *et al.* Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC, 871
 Vanhoefer U. *See* Braun A, 1099
 Varga Z. *See* Schrader AJ, 581
 Varthalitis G. *See* Razis E, 191
 Velasco J. *See* Blanco-Aparicio C, 977
 Verdin E. *See* Wittich S, 635
 Vermorken JB. *See* von Minckwitz G, 871
 Verri E. *See* Ferrari S, 733
 Versari M. *See* Ferrari S, 733
 Vetter H. *See* Stier S, 1115
 Vidal-Millan S. *See* Candelaria M, 923
 Villari D. *See* Neri B, 63
 Villman K *et al.* Predictive value of *in vitro* assessment of cytotoxic drug activity in advanced breast cancer, 609
 Voliotis D. *See* Heim M, 129
 Vormoor J. *See* Oechtering D, 337
 Vrankar M. *See* Zwitter M, 1129
 Wachowicz B. *See* Olas B, 659
 Wada H. *See* Tsuboi M, 1123
 Walten KA. *See* Gu W-Z, 1059
 Wan J-P. *See* Yeh K-H, 739
 Wang C-S. *See* Wang H-M, 447
 Wang G. *See* Ahmad KA, 1037
 Wang H-M. *See* Chen J-S, 47; *also et al.* Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx, 447; *also*
 Wang L. *See* Gu W-Z, 1059
 Wang Y *et al.* Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones, 953
 Wang Y-C. *See* Gu W-Z, 1059
 Ward MM. *See* Wang Y, 953
 Ward TH. *See* Bruce IA, 719
 Watanabe T. *See* Kawai K, 401
 Wei Y-Q. *See* Wu Y, 551
 Weichselbaum RR. *See* Mezhir JJ, 1053
 Weigert O. *See* Stemmler HJ, 747
 Wein A. *See* Hofheinz R-D, 39
 Wen Y-J. *See* Wu Y, 551
 Wenzel C *et al.* Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer, 441; *also see* Bartsch R, 617
 Whitehouse PA. *See* Mercer SJ, 495
 Willeke F. *See* Gnad-Vogt S, 435
 Willer A. *See* Gnad-Vogt S, 435
 Wiltshcke C. *See* Köstler WJ, 185
 Wittich S *et al.* Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines, 635
 Woodward JKL *et al.* Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion, 11; *also* Combined effects of zoledronic acid and doxorubicin

- on breast cancer cell invasion
in vitro, 845
- Wright JJ. *See* Lara PN, 317
- Wu JJ. *See* Shukeir N, 1045
- Wu X *et al.* The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species, 93
- Wu Y *et al.* Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine, 551
- Würthwein G. *See* Oechtering D, 337
- Xepapadakis G. *See* Markopoulos C, 879
- Xi Y. *See* Zhang Y-X, 515
- Xie C. *See* Wittich S, 635
- Xie X-J. *See* Wu Y, 551
- Yamada-Okabe H. *See* Yoneya T, 751
- Yamamoto N. *See* Enokimura N, 837
- Yamashita H. *See* Kawai K, 401
- Yamini B. *See* Mezhir JJ, 1053
- Yang L. *See* Wu Y, 551
- Yang T-S. *See* Chen J-S, 47
- Yang Y-C. *See* Liao H-F, 175
- Yazawa K. *See* Kawai K, 401
- Yeh GC. *See* Brantley E, 137
- Yeh K-H *et al.* Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung, 739
- Yeh S-H. *See* Yeh K-H, 739
- Yeh S-P. *See* Wang H-M, 447
- Yoneya T *et al.* Identification of a novel, orally bioavailable estrogen receptor downregulator, 751
- Yoon EJ. *See* Zell JA, 83
- Yu Wu X. *See* Cheung RY, 423
- Yurimoto S *et al.* Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model, 1109
- Zadinova M. *See* Sova P, 653
- Zak F. *See* Sova P, 653
- Zavrski I *et al.* Proteasome: an emerging target for cancer therapy, 475
- Zell JA *et al.* Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab, 83
- Zerbib M. *See* Mir O, 1017
- Zhang H. *See* Gu W-Z, 1059
- Zhang X-W. *See* Zhang Y-X, 515
- Zhang Y-X *et al.* 11,11'-Dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity, 515
- Zhao W-M. *See* Zhang Y-X, 515
- Zhong L. *See* Zhang Y-X, 515
- Zhou J. *See* Zhang Y-X, 515
- Zielinski CC. *See* Köstler WJ, 185; *also* Wenzel C, 441; *also* Bartsch R, 617
- Zisowsky J. *See* Heim M, 129
- Zobolas V. *See* Markopoulos C, 879
- Zolezzi C. *See* Ferrari S, 733
- Zwitter M *et al.* Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer, 1129